Core Viewpoint - Universal Ibogaine Inc. is currently under a Management Cease Trade Order (MCTO) due to delays in filing its annual audited financial statements and is providing bi-weekly updates on its default status [1][3][5]. Group 1: Default Status and Compliance - The company announced a delay in filing its annual audited financial statements for the year ended July 31, 2025, past the deadline of November 28, 2025 [2]. - A management cease trade order was granted by the Alberta Securities Commission on December 4, 2025, requiring ongoing bi-weekly default status reports [3]. - The company intends to comply with alternative information guidelines and will continue to disclose material information regarding its business activities [5]. Group 2: Restructuring Process - There have been no material changes in the company's restructuring process since the last update, and it continues to fulfill its reporting obligations [6]. - The company has temporarily closed its Kelburn Recovery Centre and is exploring financing options, including the potential sale of the property [7]. - A portion of the proceeds from any sale is intended to be used for completing the audit process and repaying outstanding convertible debt of $726,500 [13]. Group 3: Company Overview - Universal Ibogaine Inc. aims to transform addiction treatment using medicalized ibogaine and plans to conduct a clinical trial focused on opioid use disorder [9].

  Calgary, AB – TheNewswire - December 18, 2025 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to deliver medicalized ibogaine-centered addiction care, provides the following initial bi-weekly default status report update:Management Cease Trade Order (“MCTO”)Further to the Company’s prior news releases (dated November 25, 2025), the Company is providing this bi-weekly default status report (the “Default Status Report”) in accordance with National Policy ...